atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform Post published:March 30, 2022 Post category:Press Release
Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia Post published:March 30, 2022 Post category:Press Release
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform Post published:March 29, 2022 Post category:Press Release
Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin Post published:March 29, 2022 Post category:Press Release
MindMed Reports Full Year 2021 Financial Results and Business Highlights Post published:March 28, 2022 Post category:Press Release
Cybin Announces Additional Adelia Milestone Achievement Post published:March 25, 2022 Post category:Press Release
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study Post published:March 24, 2022 Post category:Press Release
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants Post published:March 24, 2022 Post category:Press Release
Psyched Wellness and the National Research Council of Canada Announce Preliminary Data from Studies of Neuroprotective Properties of AME-1 Post published:March 24, 2022 Post category:Press Release